Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580485 | 0.77 | LMNA (0.38) | — | |
| SCHEMBL8552154 | 0.77 | KDM4E (0.38) | — | |
| SCHEMBL12233349 | 0.73 | KDR (0.47) | — | |
| SCHEMBL12233317 | 0.73 | AURKA (0.47) | — | |
| SCHEMBL30110634 | 0.70 | CASP3 (0.35) | — | |
| SCHEMBL30753219 | 0.70 | CASP3 (0.35) | — | |
| SCHEMBL24126871 | 0.69 | — | — | |
| SCHEMBL31484425 | 0.69 | HTR2A (0.36) | — | |
| SCHEMBL30110578 | 0.69 | DRD2 (0.33) | — | |
| SCHEMBL1698415 | 0.69 | DRD2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4433480-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118234730-A | Heterocyclic NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115490671-B | PARP7 inhibitor and preparation method thereof | 水木未来(北京)科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-116969920-A | Fused pyridazine derivative, preparation method and medical application thereof | 上海辉启生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023088856-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | GOT1 1536/4885 |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | PTGIR, PTGIS, EDNRB | GOT1 1704/4885 |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | GOT1 3423/4885 |
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | GOT1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.